Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications

被引:8
作者
Yepmo, Melissa [1 ]
Potier, Jean-Baptiste [1 ,2 ]
Pinget, Michel [1 ]
Grabarz, Anastasia [2 ]
Bouzakri, Karim [1 ,2 ]
Bourie, Auror Dumond [1 ]
机构
[1] Univ Strasbourg, Ctr europeen Etud Diabet, Unite Mixte Rech, Diabet & Therapeut, Strasbourg, France
[2] ILONOV, Strasbourg, France
来源
FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷
关键词
NASH; NAFLD; circRNA; liver; crosstalk; hepatocellular carcinoma; insulin resistance; HEPATIC STELLATE CELLS; HEPATOCELLULAR-CARCINOMA; FIBROSIS DEVELOPMENT; THERAPEUTIC TARGET; ACTIVATION; NAFLD; NASH; STEATOHEPATITIS; METABOLISM; AUTOPHAGY;
D O I
10.3389/fendo.2022.1035159
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Circular RNAs (circRNAs) are class of non-coding RNA, which are characterized by a covalently closed loop structure. Functionally they can act on cellular physiology, notably by sponging microRNAs (miR), regulating gene expression or interacting with binding protein. To date, circRNAs might represent an interesting, underexploited avenue for new target discovery for therapeutic applications, especially in the liver. The first characteristic of non-alcoholic fatty liver disease (NAFLD) is hepatic cholesterol accumulation, followed by its advanced form of the affection, nonalcoholic steatohepatitis (NASH), due to the occurrence of lobular inflammation, irreversible fibrosis, and in some cases hepatocellular carcinoma (HCC). Therefore, studies have investigated the importance of the dysregulation of circRNAs in the onset of metabolic disorders. In this review, we summarize the potential role of circRNAs in the development of metabolic diseases associated with the liver such as NAFLD or NASH, and their potential to become therapeutic strategies for these pathologies.
引用
收藏
页数:10
相关论文
共 98 条
  • [1] Non-alcoholic fatty liver disease: The diagnosis and management
    Abd El-Kader, Shehab M.
    El-Den Ashmawy, Eman M. Salah
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (06) : 846 - 858
  • [2] Autophagy in liver diseases: Time for translation?
    Allaire, Manon
    Rautou, Pierre-Emmanuel
    Codogno, Patrice
    Lotersztajn, Sophie
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (05) : 985 - 998
  • [3] From NASH to HCC: current concepts and future challenges
    Anstee, Quentin M.
    Reeves, Helen L.
    Kotsiliti, Elena
    Govaere, Olivier
    Heikenwalder, Mathias
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (07) : 411 - 428
  • [4] NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study
    Axley, Page
    Ahmed, Zunirah
    Arora, Sumant
    Haas, Allen
    Kuo, Yong-Fang
    Kamath, Patrick S.
    Singal, Ashwani K.
    [J]. LIVER TRANSPLANTATION, 2019, 25 (05) : 695 - 705
  • [5] Macrophage functional diversity in NAFLD - more than inflammation
    Barreby, Emelie
    Chen, Ping
    Aouadi, Myriam
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2022, 18 (08) : 461 - 472
  • [6] Liver fibrosis
    Bataller, R
    Brenner, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) : 209 - 218
  • [7] The Natural Course of Non-Alcoholic Fatty Liver Disease
    Bertot, Luis Calzadilla
    Adams, Leon Anton
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
  • [8] TGF-β signaling in fibrosis
    Biernacka, Anna
    Dobaczewski, Marcin
    Frangogiannis, Nikolaos G.
    [J]. GROWTH FACTORS, 2011, 29 (05) : 196 - 202
  • [9] Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
    Boeckmans, Joost
    Gatzios, Alexandra
    Heymans, Anja
    Rombaut, Matthias
    Rogiers, Vera
    De Kock, Joery
    Vanhaecke, Tamara
    Rodrigues, Robim M.
    [J]. CELLS, 2022, 11 (05)
  • [10] Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis
    Bu, Fang-tian
    Zhu, Yan
    Chen, Xin
    Wang, Ao
    Zhang, Ya-fei
    You, Hong-mei
    Yang, Yang
    Yang, Ya-ru
    Huang, Cheng
    Li, Jun
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 23 : 847 - 862